why we created the program

---

• Engage a patient population that mirrors the epidemiology of the disease studied

• Assure the ecosystem around the trials reflects diverse populations being served. Includes research sites, principal investigators, and extended care teams

• Design in inclusivity from start

• Black Americans represent 13% of the US population but reflect only about 4% of participants in clinical trials

• Hispanics represent 16% of the US population but only about 3% of clinical trial participants

• In general 80% of patients taking part in clinical trials are white*  

• Better Science. Safety and efficacy of new medicines should be assessed in the patients with the condition

• Personalized Medicine. Understanding the range of different responses to treatments based on genetic variations

• Data. Better inform treatment decisions by making new options available to patients

• Address disparity and inequity